Concanavalin A-activated suppressor cell activity in peripheral blood lymphocytes of urologic cancer patients.
Concanavalin A (Con A)-inducible suppressor cell activity in peripheral blood lymphocytes (PBL) of urologic cancer patients and of appropriate controls with benign urologic disorders was measured concurrently. Although the proliferative responses to Con A of the cancer patients were significantly lower than those of controls, no difference in Con A-induced suppressor cell activity was demonstrated between cancer patients and controls when tested under a variety of conditions. Moreover, regression analysis revealed no correlation between the proliferative response to Con A and suppressor cell activity in either cancer patients or controls. The results indicated that Con A-inducible suppressor cell activity was unaltered in urologic cancer patients and suggested that suppressor cells of the type that can be activated by Con A were not involved in the general immunologic impairment frequently associated with urologic cancer.
D000230:Adenocarcinoma / Q000276:immunology*; D003208:Concanavalin A / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007669:Kidney Calculi / Q000276:immunology; D007680:Kidney Neoplasms / Q000276:immunology; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000276:immunology; D011471:Prostatic Neoplasms / Q000276:immunology; D011472:Prostatitis / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology*; D014525:Urethral Stricture / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000276:immunology; D014552:Urinary Tract Infections / Q000276:immunology; D014565:Urogenital Neoplasms / Q000276:immunology*
D003208:Concanavalin A